Compare

The Cooper Companies/$COO

1D1W1M3M6MYTD1Y5YMAX

About The Cooper Companies

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Ticker
$COO
Sector
Health
Primary listing
NASDAQ
Employees
15,000

COO Metrics

BasicAdvanced
$11B
20.27
$2.90
0.82
-

What the Analysts think about COO

Analyst ratings (Buy, Hold, Sell) for The Cooper Companies stock.
Analyst projections of the future price of The Cooper Companies stock.

Bulls say / Bears say

CooperSurgical’s fertility business grew 5% organically in the third quarter, helped by genomics demand, new clinic wins and further adoption of its laboratory platform. This gives the company a growing business alongside contact lenses. (The Motley Fool)
There are pockets of strong demand in CooperVision’s newer products: MyDay posted double-digit growth in several markets, while MiSight grew 20% organically. New product launches could help extend that momentum, although the segment was flat overall in the quarter. (The Motley Fool)
Cash generation was strong, with record quarterly free cash flow of $273 million, up 66% year on year. Cooper also repurchased $339 million of shares in the quarter and increased its remaining buyback authorisation to about $1.5 billion. (CooperCompanies)
Weak contact-lens sales prompted Cooper to cut its 2026 revenue and adjusted-profit forecasts; third-quarter revenue also missed analysts’ expectations. The revised annual ranges were below prior guidance and analyst estimates, leaving a higher bar for a recovery. (Reuters)
The embryo-culture-media recall has led to a $271.6 million net litigation charge, with more than 1,500 claimants reported and most settlement payments expected in fiscal 2026. The matter creates a substantial cash cost as well as ongoing legal and reputational risk. (SEC)
CEO Albert White stepped down in October, and executive chair Robert Rosebrough is overseeing day-to-day operations while a permanent successor is sought. The leadership change adds execution uncertainty as Cooper works to revive contact-lens growth. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.

COO Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

COO Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.